UNSPSC 51313300: Antihistamine or H1 blocker propylamines

Antihistamine or H1 blocker drugs made from n-propylamine, an amine, C3H9N.

UNSPSC 51313300 Antihistamine or H1 blocker propylamines is a Class code that addresses pharmaceutical procurement by state and local agencies, though recent solicitations under this code span a broader scope including naloxone, generic multi-source drugs, and over-the-counter products rather than antihistamines specifically. State and local buyers include county health departments, state health and human services commissions, and cooperative purchasing alliances serving multiple jurisdictions. Seminole County, Florida; the Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) have posted recent activity, reflecting the diversity of issuing bodies—from single counties managing community health initiatives to state-level agencies and multi-state cooperative vehicles managing pharmaceutical supply chains for dozens of participating jurisdictions.

Recent opportunities show activity concentrated in Florida and Texas with multi-state reach through cooperative purchasing. Seminole County issued IFB60459723LAS (due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with two-year initial terms and one-year renewal options. The Texas Health and Human Services Commission posted RFI HHS0017013 (due April 3, 2026) to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 (due March 26, 2026) to establish multi-award contracts for generic pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon, requiring manufacturers to work through three authorized wholesalers and demonstrating cGMP and Drug Supply Chain Security Act compliance. The cooperative purchasing vehicle structure indicates significant ongoing demand for pharmaceutical sourcing across member jurisdictions, though specific award values and budget ranges remain undisclosed.